Description:
In the phase Ib, the primary purpose is to establish the maximum tolerated dose
(MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally
administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule,
additional patients will be enrolled in the phase II portion of the study at the RP2D on the
chosen schedule in order to assess the anti-tumor activity of the combination in addition to
continued evaluation of safety.
Title
- Brief Title: A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
- Official Title: A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Clinical Trial IDs
- ORG STUDY ID:
CMEK162X2114
- SECONDARY ID:
C4211005
- NCT ID:
NCT01781572
Conditions
- Locally Advanced or Metastatic NRAS Mutant Melanoma
Interventions
Drug | Synonyms | Arms |
---|
LEE011 | | Phase II |
MEK162 | | Phase II |
Purpose
In the phase Ib, the primary purpose is to establish the maximum tolerated dose
(MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally
administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule,
additional patients will be enrolled in the phase II portion of the study at the RP2D on the
chosen schedule in order to assess the anti-tumor activity of the combination in addition to
continued evaluation of safety.
Trial Arms
Name | Type | Description | Interventions |
---|
Phase Ib | Experimental | The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.
Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).
Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).
Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle). | |
Phase II | Experimental | The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.
Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination. | |
Eligibility Criteria
Inclusion Criteria:
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0 - 1.
- Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients
enrolled into the phase II expansion must have at least one measurable lesion as
defined by RECIST 1.1 criteria for solid tumors.
- Patients must have adequate organ function, as defined by the following parameter
1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.
2. Hemoglobin (Hgb) ≥ 9 g/dL.
3. Platelets ≥ 75 x 109/L without transfusions within 21 days before 1st treatment.
4. PT/INR and aPTT ≤ 1.5 ULN.
5. Serum creatinine ≤1.5 ULN.
6. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN).
7. AST and ALT ≤ 3 x ULN, except in patients with tumor involvement of the liver who
must have AST and ALT ≤ 5 x ULN.
Exclusion Criteria:
- Presence of any brain metastases detected by MRI or CT with i.v. contrast of the brain
at screening.
- Uncontrolled arterial hypertension despite medical treatment
- Impaired cardiac function or clinically significant cardiac diseases, including any of
the following:
1. Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated
acquisition scan (MUGA) or echocardiogram (ECHO).
2. Congenital long QT syndrome or family history of unexpected sudden cardiac death.
3. QTcF corrected with Frederica's or Bazett's formula QTcB >450 ms for males and
>470 ms for females on screening ECG.
4. Angina pectoris ≤ 3 months prior to starting study drug
5. Acute myocardial infarction ≤ 3 months prior to starting study drug
6. Clinically significant resting bradycardia
7. History or presence of ventricular tachyarrhythmia
8. Unstable atrial fibrillation (ventricular response >100 bpm)
9. Complete left bundle branch block
10. Right bundle branch block and left anterior hemi block (bifascicular block)
11. Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator
12. Any other clinically significant heart disease
- Patients who are currently receiving treatment with agents that are known to cause QTc
prolongation in humans.
- Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,
inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal
muscular atrophy) or elevated baseline CK levels (≥ Grade 2)
- Patients who are currently receiving treatment with agents that are metabolized
predominantly through CYP3A4 and that have a narrow therapeutic window.
- Patients with concurrent severe and/or uncontrolled concurrent medical conditions that
could compromise participation in the study (i.e. uncontrolled diabetes mellitus,
clinically significant pulmonary disease, clinically significant neurological
disorder, active or uncontrolled infection).
- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
or hypercoagulability syndromes).
Other protocol related inclusion/exclusion criteria may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of Dose Limiting Toxicities (Phase Ib) |
Time Frame: | first 28 days of treatment |
Safety Issue: | |
Description: | To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination. A dose-limiting toxicity (DLT) was defined as an AE or clinically significant abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle of treatment with ribociclib and binimetinib. |
Secondary Outcome Measures
Measure: | Plasma Concentration-time Profile (AUCtau) of LEE011 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (AUCtau) of MEK162 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (AUCtau,ss) of LEE011 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (AUCtau,ss) of MEK162 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Cmin,ss) of LEE011 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Cmin,ss) of MEK162 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Cmax) of LEE011 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Cmax) of MEK162 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Cmax,ss) of LEE011 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Cmax,ss) of MEK162 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Tmax) of LEE011 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Tmax) of MEK162 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Tmax,ss) of LEE011 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Tmax,ss) of MEK162 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of LEE011 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of MEK162 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (T1/2,ss) of LEE011 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (T1/2,ss) of MEK162 (Phase Ib) |
Time Frame: | For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (CL/F) of LEE011 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Plasma Concentration-time Profile (CL/F) of MEK162 (Phase Ib) |
Time Frame: | Cycle 1 Day 1 |
Safety Issue: | |
Description: | To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib). |
Measure: | Number of Participants With Adverse Drug Reactions |
Time Frame: | Approximately 12 months after FPFV |
Safety Issue: | |
Description: | Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity. |
Measure: | Duration of Response (DoR) - Phase 2 |
Time Frame: | Approximately 12 months after the FPFV |
Safety Issue: | |
Description: | To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
Please note: As clinicaltrials.gov only allows numerical data entry, the value of 999 indicates "not estimable" for confidence interval. |
Measure: | Time to Progression (TTP) - Phase 2 |
Time Frame: | Approximately 12 months after the FPFV |
Safety Issue: | |
Description: | To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer. |
Measure: | Progression Free Survival (PFS) - Phase 1b and Phase 2 |
Time Frame: | Approximately 12 months after the FPFV |
Safety Issue: | |
Description: | To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
In the Phase 1b part, patients were combined for purposes of PFS analyses based on schedule received, since too few patients received any individual dose level to allow for valid PFS estimates within the respective dose levels. This is how the data were analyses and presented for the clinical study report. |
Measure: | Overall Survival (OS) - Phase ll |
Time Frame: | Approximately 12 months after the FPFV |
Safety Issue: | |
Description: | To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer. |
Measure: | Best Overall Response (BOR) - Phase II |
Time Frame: | Approximately 12 months after the FPFV |
Safety Issue: | |
Description: | To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer. |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Pfizer |
Last Updated
December 7, 2020